Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc.
Your view on MIRM
Overview
What the company does, where it operates, and who runs it.
About Mirum Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christopher Peetz
- Headquarters
- 950 Tower Lane, Foster City, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christopher Peetz
- Headquarters
- 950 Tower Lane, Foster City, CA, US
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Mirum Pharmaceuticals, Inc., and the rating behind it. MIRM last traded at $98.22; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Mirum Pharmaceuticals, Inc.. Starting points for Mirum Pharmaceuticals, Inc.: EPS -$13.57, beta 0.49 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Mirum Pharmaceuticals, Inc.. Mirum Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Mirum Pharmaceuticals, Inc.. Trailing twelve-month EPS for Mirum Pharmaceuticals, Inc. stands at -$13.57. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Mirum Pharmaceuticals, Inc.. Mirum Pharmaceuticals, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Mirum Pharmaceuticals, Inc. valued side by side against its closest peers. Mirum Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Mirum Pharmaceuticals, Inc., and how their positions are changing. At a $5.99B market value, institutional positions materially move Mirum Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Mirum Pharmaceuticals, Inc. executives and directors. Shares of Mirum Pharmaceuticals, Inc. have traded between $36.88 and $78.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Mirum Pharmaceuticals, Inc.. Mirum Pharmaceuticals, Inc. is a $5.99B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Mirum Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Mirum Pharmaceuticals, Inc.. Coverage tracks Mirum Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.